Eli Lilly seeds a well-connected China neuro startup with drugs aiming at where Biogen, Voyager missed
When Min Li took the wraps off a $100 million round for his Bob Nelsen-backed startup last December — as with most biotech CEOs when they launch — he left a couple cards unturned.
Keen to build a first-of-its-kind neuro play in China, the GlaxoSmithKline R&D vet already had a good idea of which assets he wanted to in-license for SciNeuro, conducting Zoom negotiations from the East Coast office that he’s been somewhat stuck in since JP Morgan early in the year. Now, he’s finally ready to shine a spotlight on the first program: a slate of alpha-synuclein targeted antibody therapies from Eli Lilly.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
